Should we continue to subsidise therapeutics with uncertain efficacy? Health economic implications for icosapent ethyl-Reference-Cited by-同舟云学术

Should we continue to subsidise therapeutics with uncertain efficacy? Health economic implications for icosapent ethyl

Published:2022-09-20 Issue: Volume: Page:
ISSN:2047-4873
Container-title:European Journal of Preventive Cardiology
language:en
Short-container-title:

Author:

Morton Jedidiah I¹²³,Liew Danny⁴,Nicholls Stephen J⁵,Ademi Zanfina¹^ORCID

Affiliation:

1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University , 381 Royal Parade, Parkville, Victoria 3052 , Australia

2. School of Public Health and Preventive Medicine, Monash University , Australia

3. Baker Heart and Diabetes Institute , Australia

4. Adelaide Medical School, University of Adelaide , Australia

5. Victorian Heart Institute, Monash University , Australia

Funder

Australian Government Research Training Programme

National Health and Medical Research Council

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Epidemiology

Link

https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwac212/46075542/zwac212.pdf

Reference11 articles.

1. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia;Bhatt;N Engl J Med,2018

2. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction;Ademi;Eur J Prev Cardiol,2021

3. Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial;Nicholls;JAMA,2020

4. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy;Ridker;Circulation,2022

5. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs;Doi;Eur Heart J,2021